Lipella Pharmaceuticals 株価情報 (NASDAQ: LIPO)

最新ニュース Lipella Pharmaceuticals (NASDAQ:LIPO) 株価情報

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

RBC Capital analyst Steven Shemesh maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and lowers the price target from $189 to $182.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Williams-Sonoma, Lowers Price Target to $182

Citigroup analyst Tyler Radke maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Neutral and lowers the price target from $335 to $320.

Citigroup Maintains Neutral on Salesforce, Lowers Price Target to $320

Wedbush analyst Dan Ives highlighted nuclear energy stocks in a note released Friday and pointed to Oklo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) as the<a href="https://www.benzinga.com/markets/25/05/45583796/nuclear-stocks-oklo-nano-nuclear-constellation-energy-surge-in-friday-pre-market-whats-going-on"> star of the sector.&nbsp;</a>
What To Know: President Donald Trump is expected to sign executive orders as early as Friday to boost the nuclear energy industry by streamlining approvals for new reactors and strengthening fuel supply chains. 
Read Next:<a href="https://www.benzinga.com/news/mid-cap/25/05/45587750/uranium-stocks-surge-trumps-nuclear-push-sparks-double-digit-gains?utm_source=articleShare"> Uranium Stocks Surge: Trump&#8217;s Nuclear Push Sparks Double-Digit Gains</a>&nbsp;
The anticipated executive orders are expected to direct federal agencies to expedite permitting and siting of new nuclear facilities and instruct the Departments of Energy and Defense to identify federal lands and facilities suitable for nuclear deployment, bypassing some of the current Nuclear Regulatory Commission hurdles.
Expert Ideas: Ives pointed to Oklo as a primary beneficiary of Trump's policy changes. It plans to submit a combined license application by the end of 2025 and deploy its first commercial power plant by 2027. Increased federal support and streamlined regulation could accelerate this.
Oklo's business model of building, owning and operating its own reactors while selling power directly to customers under long-term contracts positions it well for recurring revenues and addresses common pain points in nuclear projects, Ives said.&nbsp;
He sees Oklo as "set to be a major player" in the "AI Revolution datacenter buildout."
Wedbush maintained an Outperform rating on Oklo stock and raised its price target from $45 to $55. 
Other Nuclear Stocks: The Wedbush senior analyst also highlighted other companies likely to benefit from the executive orders including nuclear energy stocks such as NuScale Power Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>), Lightbridge Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTBR#NASDAQ">LTBR</a>) and Centrus Energy Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>), as well as uranium suppliers like Energy Fuels Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>), Cameco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), Uranium Energy Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) and Nexgen Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>).&nbsp;&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/05/45568107/solar-energy-stocks-drop-as-house-approves-major-rollback-of-climate-incentives?utm_source=article">Solar Energy Stocks Drop As House Approves Major Rollback Of Climate Incentives</a></li>
</ul>
Image: Shutterstock

LTBR

Nuveen Arizona Dividend Advantage Municipal Funds 3

OKLO

UUUU

Oklo Stock To Go Nuclear? Analyst Calls It A 'Major AI Revolution Player'

Citigroup analyst Ronald Josey maintains Fiverr Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) with a Buy and raises the price target from $39 to $40.

FVRR

Citigroup Maintains Buy on Fiverr Intl, Raises Price Target to $40

<ul class="wp-block-list">
<li>Klarna shrunk its workforce by 40% over the last two years, CEO Sebastian Siemiatkowski told CNBC</li>
<li>The reduced headcount was largely due to its investment in AI and natural attrition</li>
<li>Now, which partnered with OpenAI in 2023, seems to be backpedeling a bit, announcing a hiring drive for human customer service agents</li>
</ul>
Klarna CEO Sebastian Siemiatkowski said last week that the company has shrunk its workforce by 40% thanks to its investments in AI and natural attrition.
"The truth is, the company has shrunk from about 5,000 to now almost 3,000 employees," Siemiatkowski told <a href="https://www.cnbc.com/2025/05/14/klarna-ceo-says-ai-helped-company-shrink-workforce-by-40percent.html">CNBC</a> last week. "If you go to LinkedIn and look at the jobs, you'll see how we're shrinking."
The Swedish fintech company has been an outspoken proponent of AI. In 2023, it <a href="https://www.klarna.com/international/press/klarna-brings-smoooth-shopping-to-chatgpt/">announced a partnership</a> with OpenAI, aimed at "level[ing] up the shopping experience." In February 2024, one month after introducing its OpenAI-powered AI assistant, Kalrna <a href="https://www.klarna.com/international/press/klarna-ai-assistant-handles-two-thirds-of-customer-service-chats-in-its-first-month/">said</a> it was doing the work of 700 full-time customer service agents and was on track to drive profits up $40 million that year.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
About three months later, the company reported that 87% of its employees were using generative AI in their work each day. "We push everyone to test, test, test and explore," Seimiatkowski <a href="https://www.klarna.com/international/press/90-of-klarna-staff-are-using-ai-daily-game-changer-for-productivity/">said</a> at the time. "We're aimed at achieving a new level of employee empowerment, enhancing both our team's performance and the customer experience."
According to Klarna's <a href="https://www.sec.gov/Archives/edgar/data/2003292/000162828025012824/klarnagroupplcf-1.htm">IPO prospectus</a>, which was filed in March, its full-time employee count fell from 5,527 at the end of 2022 to 3,422 at the close of 2024. The company attributed the shrinkage to its efforts to increase its use of AI and natural attrition.&nbsp;
"We have simply communicated to our employees that what we're going to do is we're gonna shrink, so we're going to stop hiring," Siemiatkowski told CNBC on May 14. "Natural attrition in a company like ours is 15-20% per year, so we shrink naturally 15-20% by people just leaving."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
However, Siemiatkowski might be pulling back on his AI investments a bit. In an interview with <a href="https://www.bloomberg.com/news/articles/2025-05-08/klarna-turns-from-ai-to-real-person-customer-service">Bloomberg</a> on May 8, he said that his pursuit of cost-cutting in customer service, which was largely fueled by investments and advancements in AI, had gone too far, and the company had begun working to hire a number of remote customer service agents.&nbsp;
"From a brand perspective, a company perspective," Siemiatkowski told Bloomberg, "I just think it's so critical that you are clear to your customer that there will be always a human if you want."
The hiring program is still in its early stages, but Siemiatkowski says he envisions it eventually replacing the few thousand customer service positions the agency currently outsources.&nbsp;
Why the change of heart? "Cost unfortunately seems to have been a too predominant evaluation factor when organizing this, what you end up having is lower quality," Siemiatkowski told Bloomberg. "Really investing in the quality of the human support is the way of the future for us."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Image: Shutterstock

Klarna Reduces Workforce By 40%, Attributes Some Of Shrinkage To Its Investment In AI

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) has outperformed the market over the past 10 years by 3.51% on an annualized basis producing an average annual return of 14.02%. Currently, HealthEquity has a market capitalization of $8.48 billion. 
Buying $100 In HQY: If an investor had bought $100 of HQY stock 10 years ago, it would be worth $369.17 today based on a price of $97.90 for HQY at the time of writing.
<h3>HealthEquity's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748013320_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Citigroup analyst Andrew Kaplowitz maintains CSW Industrials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSWI#NASDAQ">CSWI</a>) with a Neutral and raises the price target from $313 to $321.

CSWI

Citigroup Maintains Neutral on CSW Industrials, Raises Price Target to $321

Novo Nordisk A/S (NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirvana, which represents the highest price of the stock throughout its 18 phases, there are conflicting signals coming from the monthly charts as well as the company's NYSE ADR (NVO).
<h3 class="wp-block-heading">Where Is Novo in the Adhishthana Cycle?</h3>
On May 12, 2025, Novo Nordisk (OMXCOP) entered Phase 18 of its Adhishthana Cycle, which began on December 23, 2013. Since then, the stock has shown an 88.5% alignment with the Adhishthana Principles on the weekly timeframe. Phase 18 is expected to run until November 8, 2026.
<h3 class="wp-block-heading">Understanding the Guna Triads</h3>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="675" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121624/Novo-Nordisk-Adhishthana-Guna-Triads-.png" alt="Fig. 1 Novo Nordisk Phase 14, 15 &amp; 16 (Source: Adhishthan.com)" class="wp-image-13326" style="width:727px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121624/Novo-Nordisk-Adhishthana-Guna-Triads-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121624/Novo-Nordisk-Adhishthana-Guna-Triads--300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121624/Novo-Nordisk-Adhishthana-Guna-Triads--1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121624/Novo-Nordisk-Adhishthana-Guna-Triads--768x432.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 1 Novo Nordisk Phase 14, 15 &amp; 16 (Source: Adhishthan.com)</figcaption></figure>
The trajectory of Phase 18 is influenced by the structure of Phases 14, 15, and 16, which I refer to as the ‘Guna Triads.' In Novo's case, the stock showed bullishness in Phases 14 and 15, and in Phase 16, it initially rallied and then corrected. The characteristics of these triads are illustrated in the figure below.
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="675" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121331/Adhishthana-Novo-Nordisk-Triad.png" alt="Fig. 2 Novo Nordisk Guna Triads (Source: Adhishthana.com)" class="wp-image-13324" style="width:793px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121331/Adhishthana-Novo-Nordisk-Triad.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121331/Adhishthana-Novo-Nordisk-Triad-300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121331/Adhishthana-Novo-Nordisk-Triad-1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121331/Adhishthana-Novo-Nordisk-Triad-768x432.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 2 Novo Nordisk Guna Triads (Source: Adhishthana.com)</figcaption></figure>
In the case of an SSR formation (Satoguna–Satoguna–Rajoguna), the chances of the stock attaining its Nirvana increase significantly, and there is little to no chance of the typical initial decline that often marks the start of Phase 18.
However, the monthly cycle and the NYSE ADRs tell a different story.
<h3 class="wp-block-heading">Monthly Charts: A Counterpoint</h3>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="668" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121434/Novo-Nordisk-Monthly-Adhishthana-.png" alt="Fig. 3 Novo Nordisk Monthly Chart (Source: Adhishthana.com)" class="wp-image-13325" style="width:704px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121434/Novo-Nordisk-Monthly-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121434/Novo-Nordisk-Monthly-Adhishthana--300x167.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121434/Novo-Nordisk-Monthly-Adhishthana--1024x570.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/23121434/Novo-Nordisk-Monthly-Adhishthana--768x428.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 3 Novo Nordisk (NOVO_B) Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
On the monthly charts, Novo is currently in Phase 11, which typically produces a peak followed by a correction. This is consistent with the complete ‘Himalayan Formation' in line with the Adhishthana Principles. This also explains the stock's pullback since July 2024. However, the correction may not be complete.
According to the Principles, a true Phase 11 descent completes when the stock retraces to the point of the ascent's origin, which generally is Phase 9 or 10 low. This would be roughly around DKK 150, which is approximately 65 percent below current levels.
This presents a critical divergence:
<ul class="wp-block-list">
<li>Weekly Chart: Signals an incoming Nirvana move by November 2026 </li>
<li>Monthly Chart: Suggests the current peak may still be forming, with the full descent yet to play out </li>
</ul>
This could mean that the present correction in reference to the monthly charts is not a terminal decline but part of a broader Himalayan formation (ascent) on the monthly cycle.
Also worth noting, the alignment on the monthly charts is only around 60-65%, which is significantly lower than the 88.5% alignment on the weekly charts. This reduces confidence in the monthly signals at this stage.
<h3 class="wp-block-heading">Final Conclusion</h3>
Novo Nordisk's Phase 18 Nirvana target on the weekly chart stands nearly 129% above current levels, suggesting explosive potential. However, the conflict between the weekly and monthly cycles introduces a high-risk, high-reward dynamic.
While some of our clients have increased exposure as Novo enters its final phase, the conflicting signals call for caution. The stock is uniquely positioned, technically bullish on one timeframe but structurally unresolved on another.
In sum, Novo Nordisk is at a pivotal juncture. The Nirvana move may still play out, but it is best suited for institutional money and high-risk investors. Individual desks should consider using proper hedging strategies, as the monthly and weekly cycles remain in conflict, potentially triggering a &#8216;death move&#8217; for Novo as it begins its 18th Phase.

Equities

Technicals

Opinion

Signals

Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?

RBC Capital analyst Darko Mihelic maintains Toronto-Dominion Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) with a Sector Perform and raises the price target from $87 to $93.

RBC Capital Maintains Sector Perform on Toronto-Dominion Bank, Raises Price Target to $93

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler raised Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) price target from $785 to $825. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Intuit shares closed at $666.07 on Thursday. See how other analysts <a href="https://www.benzinga.com/quote/INTU/analyst-ratings">view this stock</a>.</li>
<li>Needham slashed the price target for Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) from $150 to $120. Needham analyst Tom Nikic maintained a Buy rating. Deckers Outdoor shares closed at $126.09 on Thursday. <a href="https://www.benzinga.com/quote/DECK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised U.S. Gold Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAU#NASDAQ">USAU</a>) price target from $14 to $15. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. U.S. Gold shares closed at $10.44 on Thursday. See how other analysts vie<a href="https://www.benzinga.com/quote/USAU/analyst-ratings">w this stoc</a>k.</li>
<li>WestPark Capital increased the price target for Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from $315 to $328. WestPark Capital analyst Curtis Shauger maintained a Buy rating. Workday shares closed at $272.07 on Thursday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush increased the price target for Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from $350 to $500. Wedbush analyst Daniel Ives maintained an Outperform rating. Tesla shares closed at $341.04 on Thursday. See how other analysts v<a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">iew this stock</a>.</li>
<li>Benchmark cut Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) price target from $275 to $260. Benchmark analyst David Williams maintained a Buy rating. Analog Devices shares settled at $211.93 on Thursday. <a href="https://www.benzinga.com/quote/ADI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) price target from $24 to $29. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. Delcath shares closed at $16.15 on Thursday. <a href="https://www.benzinga.com/quote/DCTH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James cut Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) price target from $145 to $130. Raymond James analyst Buck Horne reiterated a Strong Buy rating. Toll Brothers shares closed at $104.14 on Thursday.  <a href="https://www.benzinga.com/quote/TOL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup increased the price target for Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) from $125 to $140. Citigroup analyst Asiya Merchant maintained a Buy rating. Seagate shares settled at $108.86 on Thursday. <a href="https://www.benzinga.com/quote/STX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street raised Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) price target from $15 to $18. Lake Street analyst Ben Klieve maintained a Hold rating. Titan Machinery shares closed at $20.13 on Thursday. <a href="https://www.benzinga.com/quote/TITN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23111258/image-307-1024x596.png" alt="" class="wp-image-926247" style="width:677px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23111258/image-307-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23111258/image-307-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23111258/image-307-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23111258/image-307.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

DCTH

DECK

INTU

TITN

TSLA

USAU

WDAY

Tesla To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Friday

RBC Capital analyst Darko Mihelic maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Sector Perform and raises the price target from C$87 to C$93.

TSX:TD

RBC Capital Maintains Sector Perform on Toronto-Dominion Bank, Raises Price Target to C$93

-<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.na.panasonic.com%2F&amp;esheet=54257231&amp;newsitemid=20250522408472&amp;lan=en-US&amp;anchor=Panasonic+Connect+North+America&amp;index=1&amp;md5=3f011bde148f31f0d3dec9feb04349d7">Panasonic Connect North America</a>, Division of Panasonic Corporation of North America, announced its strategic partnership with Honeywell Android Products, including its rugged handhelds and tablet. The partnership simplifies the buying process for mission critical professionals across public sector, healthcare, utilities, and government seeking high-quality, reliable, and secure devices that can withstand the toughest environments.
The products accompany Panasonic Connect's industry-leading portfolio of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.na.panasonic.com%2Ftoughbook&amp;esheet=54257231&amp;newsitemid=20250522408472&amp;lan=en-US&amp;anchor=TOUGHBOOK&amp;index=2&amp;md5=adbd10392a7d006af6084dcd0bc254de">TOUGHBOOK</a>&#xAE; laptops and 2-in-1 computers, including the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.na.panasonic.com%2Ftoughbook%2Frugged-laptops-tablets%2Ftoughbook-40%3Futm_source%3Dgoogle%26utm_medium%3Dcpc%26utm_campaign%3DMobility_Just_TGHBK_Brand_EXT_SRCH_Panasonic%26utm_term%3Dtoughbook%2B40%2Bmk2%26utm_id%3Dgo_cmp-17939340716_adg-167191088794_ad-704561237985_kwd-2323715562452_dev-c_ext-_network-g_match-e_place-%26gad_source%3D1%26gbraid%3D0AAAAAod8T710CeQ-9XpEkamhtBxcCSwvQ%26gclid%3DCjwKCAjwn6LABhBSEiwAsNJrjgX4k8BnGC4kP7KsCUPd4MrZ-_AY8blRgKKt7I2Gox40kGbd8akJohoCNcgQAvD_BwE%26gclsrc%3Daw.ds&amp;esheet=54257231&amp;newsitemid=20250522408472&amp;lan=en-US&amp;anchor=TOUGHBOOK+40&amp;index=3&amp;md5=5e2c2454bee31302b64dd9d9a6b67254">TOUGHBOOK 40</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.na.panasonic.com%2Ftoughbook%2Frugged-laptops-tablets%2Ftoughbook-55%3Futm_medium%3Dcpc%26utm_source%3Dgoogle%26utm_campaign%3DMobility_Just_TGHBK_Brand_EXT_SRCH_Panasonic%26utm_term%3Dtoughbook%2B40%2Bmk2%26gclid%3DCjwKCAjwn6LABhBSEiwAsNJrjgX4k8BnGC4kP7KsCUPd4MrZ-_AY8blRgKKt7I2Gox40kGbd8akJohoCNcgQAvD_BwE&amp;esheet=54257231&amp;newsitemid=20250522408472&amp;lan=en-US&amp;anchor=TOUGHBOOK+55&amp;index=4&amp;md5=cba6254d5cda39545e6adca6413e5e55">TOUGHBOOK 55</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.na.panasonic.com%2Ftoughbook%2Frugged-laptops-tablets%2Ftoughbook-33%3Futm_medium%3Dcpc%26utm_source%3Dgoogle%26utm_campaign%3DMobility_Just_TGHBK_Brand_EXT_SRCH_Panasonic%26utm_term%3Dtoughbook%2B40%2Bmk2%26gclid%3DCjwKCAjwn6LABhBSEiwAsNJrjgX4k8BnGC4kP7KsCUPd4MrZ-_AY8blRgKKt7I2Gox40kGbd8akJohoCNcgQAvD_BwE&amp;esheet=54257231&amp;newsitemid=20250522408472&amp;lan=en-US&amp;anchor=TOUGHBOOK+33&amp;index=5&amp;md5=69b35e4bdcd8b4426fd3bdf10a6ff20a">TOUGHBOOK 33</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.na.panasonic.com%2Ftoughbook%2Frugged-laptops-tablets%2Ftoughbook-g2%3Futm_medium%3Dcpc%26utm_source%3Dgoogle%26utm_campaign%3DMobility_Just_TGHBK_Brand_EXT_SRCH_Panasonic%26utm_term%3Dtoughbook%2B40%2Bmk2%26gclid%3DCjwKCAjwn6LABhBSEiwAsNJrjgX4k8BnGC4kP7KsCUPd4MrZ-_AY8blRgKKt7I2Gox40kGbd8akJohoCNcgQAvD_BwE&amp;esheet=54257231&amp;newsitemid=20250522408472&amp;lan=en-US&amp;anchor=TOUGHBOOK+G2&amp;index=6&amp;md5=33fa3a7985274863d0dba9d35b91da96">TOUGHBOOK G2</a>, bringing customers even greater flexibility. Whether benefiting from the Android devices as standalone edge products or as a companion device with TOUGHBOOK solutions, customers can now source what they need from a single partner.
"Panasonic Connect has long been a trusted technology provider for rugged mobility and frontline workers," said Dominick Passanante, Senior Vice President &amp; General Manager for the Mobility Business at Panasonic Connect North America. "We continue to refine our position as a one-stop consultative shop for rugged mobile solutions and for supporting successful digital transformations in mission-critical industries. This partnership reflects our shared commitment to understanding and addressing the unique needs of our customers, ensuring that our offerings provide maximum value and support."
The Android devices from Honeywell that will now be available through Panasonic Connect include the Honeywell CT37 (a mobile Android handheld), Honeywell CT47 (a rugged, all-purpose Android handheld), and Honeywell RT10A (a rugged Android tablet). These products support Panasonic Connect in giving customers access to productivity tools that improve visual data capture, asset tracking and management, and connectivity and communication across operations. For more product information, visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fconnect.na.panasonic.com%2Fandroid&amp;esheet=54257231&amp;newsitemid=20250522408472&amp;lan=en-US&amp;anchor=https%3A%2F%2Fconnect.na.panasonic.com%2Fandroid&amp;index=7&amp;md5=b9163ca09f9dc4f645233ce4cbee5349">https://connect.na.panasonic.com/android</a>.
"Honeywell Productivity Solutions and Services (PSS) is delighted to embark upon this new partnership with Panasonic Connect that enables us to be stronger together to serve customers in these business-critical segments. Honeywell PSS and Panasonic Connect share a rugged heritage and highly symbiotic cultures enabling the success of our customers' productivity goals. I am excited for what the future brings as we combine our proven Android enterprise devices with Panasonic Connect's TOUGHBOOK," said Georgina Lamb, Vice President &amp; General Manager, US and Canada at Honeywell PSS.

Contracts

Panasonic Connect And Honeywell Enters Strategic Partnership To Simplify Buying Process For Mission Critical Professionals Across Public Sector, Healthcare, Utilities, and Government

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Friday.
The Dow traded down 0.70% to 41,566.04 while the NASDAQ fell 1.12% to 18,713.37. The S&amp;P 500 also fell, dropping, 0.87% to 5,791.25.
Check This Out: <a href="https://www.benzinga.com/25/05/45586356/wall-streets-most-accurate-analysts-give-their-take-on-3-industrial-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrial Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Utilities shares fell by just 0.2% on Friday.
In trading on Friday, information technology stocks dipped by 1.3%.
Top Headline
Shares of Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) fell around 14% on Friday after the company issued second-quarter EPS guidance below estimates.
Ross Stores reported quarterly earnings of $1.47 per share, which beat the Street estimate of $1.44. Quarterly revenue came in at $4.99 billion, which beat the $4.97 billion consensus estimate.
Ross Stores said it sees second-quarter GAAP EPS in a range of $1.40 to $1.55, versus the $1.65 analyst estimate. "Given the varying nature of tariff announcements, we are only providing an outlook for the second quarter at this time and are withdrawing our previously provided annual sales and earnings guidance," said Conroy.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares shot up 186% to $1.19 after the company announced new data from its Phase 2 OVATION 2 Study of IMNN-001.</li>
<li>Shares of Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) got a boost, surging 9% to $727.45 after the company reported better-than-expected third-quarter financial results and raised guidance.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares were also up, gaining 60% to $0.2149 after the company announced a business alliance with M-NEXT holdings.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares dropped 21% to $100.08 after the company reported fourth-quarter financial results for fiscal 2025 after the market close on Thursday. Deckers expects first-quarter revenue of $890 million to $910 million versus estimates of $925.86 million. The company anticipates first-quarter earnings of 62 cents to 67 cents per share versus estimates of 81 cents per share.</li>
<li>Shares of Bicara Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) were down 44% to $8.81 after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) was down, falling 17% to $18.34 following third-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $61.79 while gold traded up 1.7% at $3,349.80.
Silver traded up 0.5% to $33.40 on Friday, while copper rose 2% to $4.7730.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.18%, while Spain's IBEX 35 Index fell 1.57%. London's FTSE 100 dipped 0.43%, Germany's DAX 40 declined 1.61% and France's CAC 40 fell 1.90% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei gaining 0.47%, Hong Kong's Hang Seng Index rising 0.24%, China's Shanghai Composite Index falling 0.94% and India's BSE Sensex gaining 0.95%.
Economics
U.S. sales of new single-family homes climbed by 10.9% from the previous month to an annualized rate of 743,000 units.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

BCAX

BLMZ

IMNN

MNSO

ROST

Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook

Raymond James analyst RJ Milligan maintains Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) with a Strong Buy and lowers the price target from $28 to $26.

Raymond James Maintains Strong Buy on Kite Realty Gr Trust, Lowers Price Target to $26

RBC Capital analyst Rishi Jaluria reiterates Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Outperform and maintains $525 price target.

Reiteration

MSFT

RBC Capital Reiterates Outperform on Microsoft, Maintains $525 Price Target

Raymond James analyst RJ Milligan maintains Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) with a Outperform and lowers the price target from $117 to $110.

Raymond James Maintains Outperform on Federal Realty Investment, Lowers Price Target to $110

Citigroup analyst Asiya Merchant maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $125 to $140.

Citigroup Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $140

Raymond James analyst RJ Milligan maintains CTO Realty Growth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTO#NYSE">CTO</a>) with a Strong Buy and lowers the price target from $24 to $22.

Raymond James Maintains Strong Buy on CTO Realty Growth, Lowers Price Target to $22

Raymond James analyst RJ Milligan maintains Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) with a Strong Buy and raises the price target from $17 to $18.

NTST

Raymond James Maintains Strong Buy on Netstreit, Raises Price Target to $18

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is catching fire again as technical strength, growing retail interest,and Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surge fuel chatter about the meme coin hitting <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">the iconic $1 level</a>.
What Happened: On his May 22 <a href="https://www.youtube.com/watch?v=HBd6Yjf24dE">podcast</a>, crypto analyst Kevin said DOGE could revisit its former all-time highs near $0.95, or even break the "famous dollar level", if Bitcoin maintains upward momentum. 
He attributes this potential breakout to DOGE's strong technical structure and continued popularity with retail traders.
While Kevin says a price between $3.80 and $4.00 could be possible this cycle under exceptional conditions, his short-term focus is on the $0.26–$0.285 resistance zone, the confluence of the macro golden pocket and 200-day simple moving average. 
A breakout here could send Dogecoin toward $0.33, the measured move from a bullish flag pattern on the daily chart.
Dogecoin's fundamentals are aligning with bullish sentiment and technical (macro golden pocket), all eyes are on the $0.26–$0.285 breakout zone, with $0.33 as the next near-term target describing as "bullish flag pattern".
Trader Bluntz Capital sees DOGE breaking upward out of a channel and says a "god candle" is loading on the chart.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">these dalai lama upwards channel breakouts are always my favourite setups. god candle loading on <a href="https://twitter.com/search?q=%24doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$doge</a> <a href="https://t.co/7YvxNs13X6">pic.twitter.com/7YvxNs13X6</a>
&mdash; Bluntz (@Bluntz_Capital) <a href="https://twitter.com/Bluntz_Capital/status/1925742279655837830?ref_src=twsrc%5Etfw">May 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Bitcoinsensus <a href="https://x.com/bitcoinsensus/status/1925821066066227551?s=46">noted</a> past bull flags on DOGE delivering massive gains: the 1st flag at +90%, 2nd flag with +215%, 3rd flag generating +440%. He believes the 4th flag could lead to $0.95, a 560% spike.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45520339/is-a-dogecoin-breakout-to-0-30-brewing">Is A Dogecoin Breakout To $0.30 Brewing?</a>
Why It Matters: In an X <a href="https://x.com/wormhole/status/1925650225563099431?s=46">post</a> on May 23, interoperability protocol Wormhole announced that Dogecoin is now available on the Solana blockchain, unlocking new utility and bridging ecosystems. 
This integration could drive greater liquidity, trading volume, and cross-chain speculation, especially with Solana's high-speed infrastructure supporting DOGE.
According to Coinglass, Dogecoin liquidations fell to just $2.86 million on May 23, the lowest since May 8. 
Open interest surged 3.3% to $3.06 billion, its highest level since May 11, signaling rising market engagement.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45474296/dogecoin-up-47-in-one-month-how-much-higher-can-it-go">Dogecoin Up 47% In One Month: How Much Higher Can It Go?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

Dogecoin Climbs 2%: Can It Target $1 Soon?

Press Releases

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Health Care

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Peraso Inc. (NASDAQ: PRSO): A Critical Enabler Positioned for AI, 5G, and Telecom Growth – More Stock Pure-Plays inside….

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement

Spartan Capital Securities, LLC Announces Key February Transactions

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

Comments

Lipella Pharmaceuticals

ニュース

最新ニュース Lipella Pharmaceuticals (NASDAQ:LIPO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル